Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H36N6S |
InChIKeyUXDGHRWOHOPKIL-UHFFFAOYSA-N |
CAS Registry688342-78-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 04 Jan 2022 |